{"id":"https://openalex.org/W2979507353","doi":"https://doi.org/10.1182/blood-2018-99-115486","title":"Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","display_name":"Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2979507353","doi":"https://doi.org/10.1182/blood-2018-99-115486","mag":"2979507353"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-115486","doi":"https://doi.org/10.1182/blood-2018-99-115486","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-115486","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040703931","display_name":"Mark Blaine Geyer","orcid":"https://orcid.org/0000-0001-5248-9117","observed_orcids":["https://orcid.org/0000-0001-5248-9117"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Blaine Geyer","raw_affiliation_strings":["Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY","Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078887304","display_name":"Ellen Kelly Ritchie","orcid":"https://orcid.org/0000-0001-8150-5542","observed_orcids":["https://orcid.org/0000-0001-8150-5542"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ellen K. Ritchie","raw_affiliation_strings":["Weill Cornell Medical College, Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Cornell Medical College, Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056698355","display_name":"Arati V. Rao","orcid":"https://orcid.org/0009-0004-2922-710X","observed_orcids":["https://orcid.org/0009-0004-2922-710X"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arati V. Rao","raw_affiliation_strings":["Gilead Sciences, Inc, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015214048","display_name":"M. Isabella Cazacu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"M. Isabella Cazacu","raw_affiliation_strings":["Leukemia Service, Department of Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, New York, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086407321","display_name":"Shreya Vemuri","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Shreya Vemuri","raw_affiliation_strings":["Sloan Kettering Institute, 1275 York Avenue, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sloan Kettering Institute, 1275 York Avenue, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001124933","display_name":"Martin S. Tallman","orcid":"https://orcid.org/0000-0002-4367-6102","observed_orcids":["https://orcid.org/0000-0002-4367-6102"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin S. Tallman","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111663910","display_name":"Dan Douer","orcid":"https://orcid.org/0000-0002-3693-8864","observed_orcids":["https://orcid.org/0000-0002-3693-8864"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dan Douer","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101838284","display_name":"Jae H. Park","orcid":"https://orcid.org/0000-0002-2903-5130","observed_orcids":["https://orcid.org/0000-0002-2903-5130","https://orcid.org/0009-0003-2678-9513"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jae H. Park","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5015214048","https://openalex.org/A5086407321"],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"4013","last_page":"4013"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/philadelphia-chromosome-negative-acute-lymphoblastic-leukemia","display_name":"Philadelphia chromosome-negative acute lymphoblastic leukemia","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pegaspargase","display_name":"pegaspargase","score":0.8859999775886536},{"id":"https://openalex.org/keywords/pediatric-inspired-chemotherapy","display_name":"pediatric-inspired chemotherapy","score":0.8799999952316284},{"id":"https://openalex.org/keywords/minimal-residual-disease-negativity","display_name":"minimal residual disease negativity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/asparaginase-toxicity","display_name":"asparaginase toxicity","score":0.8569999933242798},{"id":"https://openalex.org/keywords/hyperbilirubinemia","display_name":"hyperbilirubinemia","score":0.8510000109672546},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.699999988079071},{"id":"https://openalex.org/keywords/consolidation-therapy","display_name":"consolidation therapy","score":0.32199999690055847},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.5960000157356262},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.42100000381469727}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7511715888977051},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.652970016002655},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6265321969985962},{"id":"https://openalex.org/C2778904437","wikidata":"https://www.wikidata.org/wiki/Q105296036","display_name":"Asparaginase","level":4,"score":0.5321881771087646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5209354162216187},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.49513283371925354},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.4457448720932007},{"id":"https://openalex.org/C2781107101","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Acute lymphocytic leukemia","level":4,"score":0.44301629066467285},{"id":"https://openalex.org/C2777478502","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic lymphoma","level":4,"score":0.4399719834327698},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4291742444038391},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4164324998855591},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.37205034494400024},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.331781804561615},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.3182213008403778},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2825459837913513},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.24457669258117676},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19523915648460388},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.07461914420127869},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.0},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-115486","doi":"https://doi.org/10.1182/blood-2018-99-115486","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-115486","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3093090760","https://openalex.org/W2608464015","https://openalex.org/W4413767041","https://openalex.org/W2131521161","https://openalex.org/W7168017048","https://openalex.org/W4389234965","https://openalex.org/W4386024146","https://openalex.org/W2980143174","https://openalex.org/W2589503004","https://openalex.org/W3155294922"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Among":[2],"adolescents":[3],"and":[4,30,134,184,187,220,291,309,358,421,484,488,506,526,595,617,628],"young":[5],"adults":[6,46,95,549,651],"with":[7],"(w/)":[8],"acute":[9],"lymphoblastic":[10,14],"leukemia":[11],"(ALL)":[12],"or":[13,109,326,336,413,454,740,756,785],"lymphoma":[15],"(LBL),":[16],"treatment":[17,115,228,444],"using":[18],"a":[19,67,89,588,598,703],"pediatric":[20,42],"(vs.":[21],"adult)":[22],"regimen":[23,70,116],"appears":[24],"to":[25,78,289,304,551,597],"achieve":[26],"superior":[27],"event-free":[28],"(EFS)":[29],"overall":[31],"survival":[32],"(OS);":[33],"this":[34],"observation":[35],"has":[36,471],"driven":[37],"increased":[38],"interest":[39],"in":[40,62,94,149,169,247,256,258,265,299,431,480,491,587],"adapting":[41],"regimens":[43,61,542],"for":[44,546],"middle-aged":[45],"w/":[47,55,71,82,98,106,126,213,234,243,315,328,373,377,403,405,462,464,543,554,620],"ALL/LBL.":[48,556],"However,":[49],"greater":[50],"risk":[51,647],"of":[52,59,73,118,129,140,151,156,160,182,194,227,278,281,351,443,447,496,567,591,601,648,738,754,783],"toxicities":[53,81,241],"associated":[54,242],"asparaginase":[56,614],"complicates":[57],"administration":[58],"pediatric-inspired":[60,68,540],"adults.":[63],"We":[64,87],"therefore":[65],"designed":[66],"chemotherapy":[69,541],"doses":[72,280],"pegaspargase":[74],"(PEG)":[75],"rationally":[76],"synchronized":[77],"limit":[79],"overlapping":[80],"other":[83,360],"chemotherapeutic":[84],"agents.":[85],"Methods:":[86],"conducted":[88],"phase":[90],"II":[91],"multi-center":[92],"trial":[93],"ages":[96],"18-60":[97],"newly-diagnosed":[99],"Philadelphia":[100],"chromosome-negative":[101],"(Ph-)":[102],"ALL/LBL":[103],"(NCT01920737).":[104],"Pts":[105,270],"Ph+":[107],"ALL":[108,111,374,463],"Burkitt-type":[110],"were":[112,201,209],"ineligible.":[113],"The":[114],"consisted":[117],"2-phase":[119],"induction":[120,584],"(I-1,":[121],"I-2),":[122],"followed":[123,136],"by":[124,137,173,203,387,396,417],"consolidation":[125,272,643],"2":[127,478],"courses":[128,155,585],"alternating":[130],"high-dose":[131],"methotrexate-based":[132],"intensification":[133],"reinduction,":[135],"3":[138,489],"years":[139,231],"maintenance":[141],"(Figure":[142,508],"1).":[143],"PEG":[144,244,282,290,296,535,580],"2000":[145],"IU/m2":[146],"was":[147,167,197,229,253,297,354,521,529,572,581],"administered":[148],"each":[150],"the":[152,359,371,401,459],"6":[153,279,449],"intensive":[154],"induction/consolidation":[157],"at":[158,225,437,517],"intervals":[159],"\u22654":[161],"weeks.":[162],"Minimal":[163],"residual":[164],"disease":[165],"(MRD)":[166],"assessed":[168,202],"bone":[170],"marrow":[171,363],"(BM)":[172],"multiparameter":[174],"flow":[175],"cytometry":[176],"(FACS)":[177],"on":[178,273,734,750,779],"day":[179],"(d)":[180],"15":[181],"I1":[183],"following":[185,333,389,398,419,467],"I-1":[186,257,334,420],"I-2.":[188,369,399,422],"Any":[189],"detectable":[190],"MRD":[191,380,386,395,408,416,466,592],"(even":[192],"<0.01%":[193],"BM":[195,379,407],"WBCs)":[196],"considered":[198],"positive.":[199],"Toxicities":[200],"CTCAE":[204],"v4.0.":[205],"Results:":[206],"39":[207],"pts":[208,236,267,286,302,314,340,353,372,402,424,434,461,479,490,501,563],"enrolled":[210],"(30M,":[211],"9F),":[212],"B-ALL":[214],"(n=28),":[215],"T-ALL":[216],"(n=7),":[217],"B-LBL":[218],"(n=3),":[219],"T-LBL":[221],"(n=5).":[222],"Median":[223],"age":[224,237,552],"start":[226,442],"38.3":[230],"(range":[232],"20.2-60.4),":[233],"18":[235],"40-60.":[238],"Grade":[239,250,569],"3-4":[240,251,570],"are":[245,560],"summarized":[246],"Table":[248],"1.":[249],"hyperbilirubinemia":[252,571],"observed":[254],"post-PEG":[255],"9":[259],"pts,":[260],"but":[261,576],"only":[262,469],"recurred":[263,577],"thereafter":[264],"1/8":[266],"resuming":[268],"PEG.":[269],"completing":[271],"protocol":[274],"(n=16)":[275],"received":[276,293],"median":[277,438,494,504],"(range,":[283,445,502],"2-6).":[284],"Four":[285],"developed":[287],"hypersensitivity":[288],"subsequently":[292,450],"Erwinia":[294],"asparaginase.":[295,568],"discontinued":[298],"4":[300],"additional":[301],"due":[303],"hepatotoxicity":[305],"(n=2),":[306],"pancreatitis":[307],"(n=1),":[308],"physician":[310],"preference":[311],"(n=1).":[312,338],"Of":[313,370,400,458],"available":[316,378,406],"response":[317,324],"assessments,":[318,381,409],"35/36":[319],"(97%)":[320],"achieved":[321,366,384,393,412],"morphologic":[322],"complete":[323],"(CR)":[325],"CR":[327,367],"incomplete":[329],"hematologic":[330],"recovery":[331],"(CRi)":[332],"(n=34)":[335],"I-2":[337],"Both":[339],"not":[341,511,515],"achieving":[342],"CR/CRi":[343],"after":[344,364,368],"I-I":[345],"had":[346],"early":[347],"T-precursor":[348],"ALL;":[349],"one":[350,470],"these":[352],"withdrawn":[355],"from":[356,441],"study,":[357],"(w/":[361],"M2":[362],"I-1)":[365],"(excluding":[375],"LBL)":[376],"11/28":[382],"(39%)":[383],"undetectable":[385,394,415,465],"FACS":[388,397,418],"I-1;":[390],"18/22":[391],"(82%)":[392],"LBL":[404],"7/7":[410],"(100%)":[411],"maintained":[414],"Ten":[423],"underwent":[425,451],"allogeneic":[426],"hematopoietic":[427],"cell":[428],"transplantation":[429],"(alloHCT)":[430],"CR1.":[432],"Seven":[433],"experienced":[435],"relapse":[436,649],"15.2":[439],"months":[440,498],"5.4-30.4),":[446],"whom":[448],"1st":[452],"(n=5)":[453],"2nd":[455],"(n=1)":[456],"alloHCT.":[457],"11":[460],"I-1,":[468],"relapsed.":[472],"Five":[473],"patients":[474],"have":[475,510],"died,":[476],"including":[477],"CR1":[481],"(from":[482],"sepsis":[483],"multi-organ":[485],"system":[486],"failure),":[487],"relapse.":[492,602],"At":[493],"follow-up":[495,605],"22.3":[497],"among":[499,650],"surviving":[500],"1.0-48.1),":[503],"EFS":[505,520,609],"OS":[507,528],"2A&B)":[509],"been":[512],"reached":[513],"(EFS":[514],"censored":[516],"alloHCT).":[518],"3-year":[519,527,608],"62.1%":[522],"(95%":[523,531],"CI:":[524,532],"38.4-78.9%)":[525],"80.0%":[530],"57.5-91.4%).":[533],"Conclusions:":[534],"can":[536],"be":[537,625],"incorporated":[538],"into":[539,641],"manageable":[544],"toxicity":[545],"appropriately":[547],"selected":[548],"up":[550],"60":[553],"Ph-":[555],"While":[557],"PEG-related":[558],"AEs":[559],"common,":[561,573],"few":[562],"require":[564],"permanent":[565],"discontinuation":[566],"particularly":[574],"post-I-1,":[575],"infrequently":[578],"when":[579],"continued.":[582],"Two":[583],"resulted":[586],"high":[589],"rate":[590,600],"negativity":[593],"post-I-2":[594],"translated":[596],"low":[599],"Though":[603],"further":[604],"is":[606,610],"required,":[607],"encouraging.":[611],"Data":[612],"regarding":[613],"enzyme":[615],"activity":[616],"silent":[618],"inactivation":[619],"neutralizing":[621],"anti-PEG":[622],"antibody":[623],"will":[624,631],"presented.":[626],"Ongoing":[627],"future":[629],"studies":[630],"additionally":[632],"investigate":[633],"whether":[634],"incorporating":[635],"novel":[636],"therapies":[637],"(e.g.":[638],"blinatumomab,":[639],"nelarabine)":[640],"frontline":[642],"therapy":[644],"may":[645],"reduce":[646],"receiving":[652],"PEG-containing":[653],"regimens.":[654],"Disclosures":[655],"Geyer:":[656],"Dava":[657],"Oncology:":[658],"Honoraria.":[659],"Ritchie:Celgene:":[660],"Consultancy,":[661,673,689,699,773,777],"Other:":[662,690,708,721,725],"Travel,":[663,691],"Accommodations,":[664,692],"Expenses,":[665,693],"Speakers":[666,674,678,696,743,759],"Bureau;":[667,675,679,697,744,760],"NS":[668],"Pharma:":[669,681,769],"Research":[670,682,686,694,700,712,715,718,730,774],"Funding;":[671,683,687,713,716,719,775],"Incyte:":[672],"ARIAD":[676],"Pharmaceuticals:":[677,762],"Astellas":[680],"Bristol-Myers":[684],"Squibb:":[685],"Novartis:":[688,790],"Funding,":[695],"Pfizer:":[698,764,794],"Funding.":[701,731],"Rao:Kite,":[702],"Gilead":[704,745],"Company:":[705],"Employment.":[706],"Tallman:Daiichi-Sankyo:":[707],"Advisory":[709,722,726],"board;":[710,723,727],"AROG:":[711],"Cellerant:":[714],"AbbVie:":[717],"BioSight:":[720],"Orsenix:":[724],"ADC":[728],"Therapeutics:":[729,772],"Douer:Shire:":[732],"Membership":[733,749,778],"an":[735,751,780],"entity's":[736,752,781],"Board":[737,753,782],"Directors":[739,755,784],"advisory":[741,757,786],"committees,":[742,758],"Sciences:":[746],"Consultancy;":[747,763,770,789,791,793,795],"Amgen:":[748,776],"Jazz":[761],"Honoraria;":[765],"Spectrum:":[766],"Consultancy.":[767,798],"Park:Kite":[768],"Juno":[771],"committees;":[787],"AstraZeneca:":[788],"Shire:":[792],"Adaptive":[796],"Biotechnologies:":[797]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":3}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2019-10-18T00:00:00"}